220 Participants Needed

TAR-200 + Cetrelimab for Bladder Cancer

(SunRISe-1 Trial)

Recruiting at 172 trial locations
SC
Overseen ByStudy Contact
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Janssen Research & Development, LLC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a drug-delivery device (TAR-200) and an immune-boosting drug (cetrelimab) in bladder cancer patients who have not responded well to other treatments. TAR-200 releases medicine directly into the bladder, while cetrelimab helps the immune system fight cancer. Cetrelimab is being studied in patients with different types of bladder cancer.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is the TAR-200 treatment safe for bladder cancer patients?

TAR-200, a system that releases gemcitabine directly into the bladder, has been studied for safety in patients with muscle-invasive bladder cancer. The studies found it to be generally safe and tolerable for patients who were either unfit for or refused more aggressive treatments.12345

What makes the TAR-200 + Cetrelimab treatment unique for bladder cancer?

TAR-200 is a unique treatment for bladder cancer because it uses an intravesical drug delivery system to release gemcitabine directly into the bladder over a 21-day cycle, providing localized treatment with potentially fewer side effects compared to systemic chemotherapy. Cetrelimab, combined with TAR-200, may enhance the immune response against cancer cells, offering a novel approach for patients who are unfit for traditional therapies.12567

What data supports the effectiveness of the treatment TAR-200 + Cetrelimab for bladder cancer?

Research shows that TAR-200, which releases gemcitabine directly into the bladder, has been found to be safe and potentially effective in patients with muscle-invasive bladder cancer who cannot undergo standard treatments. Additionally, gemcitabine has shown promising results in improving survival in patients with metastatic bladder cancer.12378

Who Is on the Research Team?

JR

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Are You a Good Fit for This Trial?

This trial is for adults with high-risk non-muscle invasive bladder cancer that hasn't responded to BCG therapy and who can't have or chose not to undergo bladder removal surgery. They should be mostly urothelial cancer type, without certain aggressive features, and must have a performance status that allows daily living activities.

Inclusion Criteria

I am able to care for myself and perform daily activities.
My bladder cancer did not respond to a full course of BCG treatment.
My tumor is mainly urothelial but doesn’t have certain aggressive features.
See 5 more

Exclusion Criteria

I have not received a live virus vaccine in the last 30 days.
I don't have active hepatitis B or C, or it's undetectable.
My bladder cancer has not spread outside the bladder, except possibly for early-stage cancer in the upper urinary tract treated over 2 years ago.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive TAR-200 and/or Cetrelimab based on cohort assignment. TAR-200 is dosed every 3 weeks for up to 24 weeks, then every 12 weeks through Week 99. Cetrelimab is dosed every 3 weeks through Week 78.

Up to 99 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments of complete response rate and disease-free survival.

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Cetrelimab
  • TAR-200
Trial Overview The study tests TAR-200 (a drug-device combination) and Cetrelimab (an immunotherapy), alone or in combination, in four different participant groups based on their specific type of bladder cancer. The main goals are to see if the treatments completely remove the cancer or prevent it from returning.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Cohort 4: TAR-200 (Participants with Papillary Disease only)Experimental Treatment1 Intervention
Group II: Cohort 3: CetrelimabExperimental Treatment1 Intervention
Group III: Cohort 2: TAR-200Experimental Treatment1 Intervention
Group IV: Cohort 1: TAR-200 and CetrelimabExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials
1,022
Recruited
6,408,000+
Joaquin Duato profile image

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD profile image

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Published Research Related to This Trial

TAR-200, a novel drug delivery system for gemcitabine, was found to be generally safe and well tolerated in a study of 35 elderly patients with muscle-invasive bladder cancer who were unfit for standard treatment.
The treatment showed promising preliminary efficacy, with a 40% overall response rate and a median overall survival of 27.3 months, indicating it could be a valuable option for patients with limited treatment choices.
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.Tyson, MD., Morris, D., Palou, J., et al.[2023]
The TAR-200 system for delivering gemcitabine directly into the bladder was found to be safe and well tolerated in a phase I study involving 23 patients with muscle-invasive bladder cancer (MIBC), with no intolerable side effects reported.
Preliminary efficacy results showed that a significant number of patients experienced pathologic downstaging after treatment, with some achieving complete or partial responses, indicating potential effectiveness of this localized treatment approach.
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.Daneshmand, S., Brummelhuis, ISG., Pohar, KS., et al.[2022]
The combination of gemcitabine and irinotecan (Irinogem) showed promising efficacy in treating metastatic bladder cancer, with 8 out of 13 evaluable patients achieving an objective response, including 2 complete responses and 6 partial responses, and a median progression-free survival of 8.78 months.
The treatment was associated with manageable toxicity, with no toxic deaths reported, although some patients experienced significant side effects like neutropenia and diarrhea. However, the study's early closure due to funding issues limits the ability to draw definitive conclusions.
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.Chaudhary, UB., Verma, N., Keane, T., et al.[2022]

Citations

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. [2023]
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. [2022]
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. [2022]
Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. [2020]
Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. [2017]
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. [2022]
Atezolizumab in invasive and metastatic urothelial carcinoma. [2019]
8.Czech Republicpubmed.ncbi.nlm.nih.gov
[Immunotherapy for Bladder Cancer]. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security